Research

First study to show waning effectiveness of 3rd dose of mRNA vaccines

A nationwide study from the U.S. Centers for Disease Control and Prevention (CDC) is the first to show that immunity against severe COVID-19 disease begins to wane 4 months after receipt of the third dose of an mRNA vaccine (Pfizer or Moderna). Waning immunity was observed during both the Delta and Omicron variant waves in similar fashion to how mRNA vaccine effectiveness wanes after a second dose.

Promising molecule for treatment of COVID-19

Uppsala researchers have succeeded in designing a molecule that inhibits the replication of coronaviruses and that has great potential for development into a drug suitable for treating COVID-19. The molecule is effective against both the new variant and previously identified coronaviruses. The article has been published in the Journal of the American Chemical Society.

Scientists identified vulnerable site on multiple coronaviruses

The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. The discovery, published in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping future coronavirus pandemics.

Suppressing the spread of tumors

Why some patients develop metastases and others do not is largely unclear. Researchers around ISTA professor Daria Siekhaus are now contributing to a better understanding of the process in certain types of cancer. They took a close look at the role of a protein called MFSD1 - the mammalian relative of a protein they had previously identified as affecting cell migration in fruit flies.

With personalized medicine, a shelved cancer drug could get another shot

A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which is the most aggressive form of breast cancer and has few targeted therapies.

Computer predicted life saving benefit of Baricitinib for ventilated COVID patients

Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation (ECMO) lived more often when randomized to receive baricitinib. Doctors call this drug 'bari,' and receiving the pill once a day for up to 14 days yielded one of the largest a survival advantages seen yet in the COVID pandemic, according to a study published in The Lancet Respiratory Medicine.

Three exposures to spike protein allow people to develop broad antibody immunity - also against Omicron

Scientists from Ludwig-Maximilians-Universitaet (LMU) in Munich, Helmholtz Munich, and Technical University of Munich have shown that the immune system is capable of neutralizing even Omicron after a total of three exposures to the viral spike protein.

Since the beginning of the COVID-19 pandemic, SARS-CoV-2 has continued to evolve, with new variants of concern (VoCs) spreading rapidly.

First study to show waning effectiveness of 3rd dose of mRNA vaccines

Promising molecule for treatment of COVID-19

Scientists identified vulnerable site on multiple coronaviruses

Suppressing the spread of tumors

With personalized medicine, a shelved cancer drug could get another shot

Computer predicted life saving benefit of Baricitinib for ventilated COVID patients

Three exposures to spike protein allow people to develop broad antibody immunity - also against Omicron

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs